Loading page...

Back
PAR-25-070 Open
Send to:
National Institutes of Health United States

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

Open Education, health Posted 18 Nov 2024
Deadline 7 Jan 2027 56 days left

Overview

Funding agency
National Institutes of Health HHS-NIH11
Reference
PAR-25-070
Funding programme
Education, health
Funding instrument
Grant
Cost sharing
Not required
Region
United States
Applicants based in
United States
Source
Grants.gov (US Federal)

About the funder

Funder
National Institutes of Health Research council, United States
Grants in 2025
129 Typical grant $700k
Open calls
646 open calls Giving history, how to apply, and Follow on the funder page

Description

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these…

Sign up to view full grant details

Create a free account to unlock the complete grant description, funding details, eligibility criteria, and application links.

Full description Funding amounts & eligibility Application links & deadlines Save & track grants

Related grants

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required) National Institutes of Health Closes 13 Nov 2026 NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) National Institutes of Health Closes 13 Nov 2026 NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) National Institutes of Health Closes 13 Nov 2026
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) National Institutes of Health Closes 17 Nov 2026 Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required) National Institutes of Health Closes 7 Jan 2027 National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) National Institutes of Health Closes 7 Jan 2027

Send to CRM

CRM Integration Required

To send grants directly to your CRM, you need to connect your CRM system to TenderPipe first.

Configure CRM in Settings

Email Grant

Scroll to Top